论文部分内容阅读
目的使放射免疫显像诊断膀胱癌更加简便、安全、可靠。方法采用抗人膀胱癌单克隆抗体ＢＤＩ－１通过２－巯基乙醇直接还原法标记９９ｍＴｃ（９９ｍＴｃ）制备了９９ｍＴｃ－ＢＤＩ－１。结果标记率为６９．９％，放化纯度大于９５％。３３例患者接受了通过膀胱内灌注的放射免疫显像诊断，其中４例非膀胱癌患者均未见显像，２９例膀胱癌患者肿瘤显像阳性率为８８．５％。原发和复发肿瘤均可获得清晰的显像，显像肿瘤最小为０．５ｃｍ，肿瘤细胞分级包括Ｇ１～Ｇ３。显像结果与膀胱镜检结果完全符合者占６５．２％，１１例多发肿瘤中有７例（６３．６％）显像结果在肿瘤数目、位置及大小上与膀胱镜检有所差异。结论该方法为膀胱癌的诊断提供了一种新的安全有效的手段。
The purpose of radioimmunoimaging diagnosis of bladder cancer is more simple, safe and reliable. Methods 99mTc-BDI-1 was prepared by the anti-human bladder cancer monoclonal antibody BDI-1 by 99mTc (99mTc) direct labeling with 2-mercaptoethanol. Results marked rate of 69.9%, radiochemical purity greater than 95%. Thirty-three patients were diagnosed by radioimmunoassay via intravesical instillation. None of the 4 patients with bladder cancer showed any imaging. The positive rate of tumor imaging in 29 patients with bladder cancer was 88.5%. Clear imaging of primary and recurrent tumors can be obtained. The minimum tumor size is 0.5 cm and the grade of tumor cells is G1 to G3. Imaging results were consistent with cystoscopy results accounted for 65.2%, 11 cases of multiple tumors in 7 cases (63.6%) imaging results in tumor size, location and size and cystoscopy were different. Conclusion This method provides a new safe and effective method for the diagnosis of bladder cancer.